Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASH 2025 MPNs Highlights
29 January 2026 | Virtual Webinar
Post-ASH 2025 MPNs Highlights
Featuring presentations & discussions on selected MPNs abstracts from the 67th ASH Annual Meeting and Exposition
Thursday 29 January | 10:00 – 12:00 CST/ 16:00 – 18:00 GMT/ 17:00 – 19:00 CET
Chair: Claire Harrison | Moderators: Francesca Palandri and John Mascarenhas
The Post-ASH 2025 MPN Highlights is supported by BMS (Platinum Sponsor), Takeda (Gold Sponsor) and Sumitomo Pharma (Silver Sponsor). Supporters have no influence over the production of content.
Explore the presentations & panel discussions below:
Session 1: Advances in the management of PV and ET
Rusfertide or placebo plus current SoC therapy for polycythemia vera: findings from the Phase III VERIFY study
Andrew Kuykendall Moffitt Cancer Center, Tampa, FL, United States
Ropeginterferon alfa-2b in essential thrombocythemia: 12-month primary endpoint analysis from the Phase III ROP-ET study
Jean-Jacques Kiladjian Saint-Louis Hospital & Paris Diderot University, Paris, France
Panel Discussion
Session 2: Latest in MF therapies
Updated results from the Phase II RESTORE trial: elritercept (KER-050, TAK-226) in patients with myelofibrosis receiving ruxolitinib
Ciro Rinaldi Lincoln Hospital, Lincoln, United Kingdom
Pelabresib plus ruxolitinib in JAK Inhibitor–naive myelofibrosis: 96-week results from the Phase III MANIFEST-2 study
Raajit Rampal Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Preliminary data from the Phase I/II study of nuvisertib in combination with momelotinib in patients with R/R myelofibrosis
John Mascarenhas Icahn School of Medicine at Mount Sinai, New York City, NY, United States
FEDORA: Phase II study evaluating the tolerability, safety and activity of fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis
Mary Frances McMullin Queen's University Belfast, Belfast, United Kingdom
Interim analysis of PROMISE: OPN-2853 in combination with ruxolitinib in patients with advanced MF experiencing an inadequate response to ruxolitinib
Adam Mead University of Oxford, Oxford, United Kingdom
Safety and efficacy of INCA033989 as monotherapy or in combination with ruxolitinib in patients with MF: preliminary results
John Mascarenhas Icahn School of Medicine at Mount Sinai, New York City, NY, United States
Panel Discussion
Session 3: Novel therapeutic approaches for MPNs and mastocytosis
Venetoclax and decitabine in MPN-BP: results of the Phase II ENABLE trial
Alessandro Vannucchi University of Florence, Florence, Italy
Genome editing for treatment of JAK2 V617F-driven myeloproliferative neoplasms
Roman Doll University of Oxford, Oxford, United Kingdom
Menin inhibition as a new therapeutic option for the myeloproliferative neoplasms
John Crispino St Jude Children's Research Hospital, Memphis, TN, United States
Panel Discussion
